Paving the Critical Path for Innovation in the Biotechnology Industry
This article was originally published in RPM Report
Executive Summary
Sandoz CEO Andres Rummelt and senior executives explain why the time is ripe for biogenerics in the US.
You may also be interested in...
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
Drug companies looking to bring biosimilars to the U.S. market will use existing regulatory pathways like 505(b)(2) or an outright Biologics Licensing Application over a new regulatory pathway provided in the health care reform legislation because of provisions in the new pathway that favor brands, Jeff George, the head of Sandoz, predicted
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
Drug companies looking to bring biosimilars to the U.S. market will use existing regulatory pathways like 505(b)(2) or an outright Biologics Licensing Application over a new regulatory pathway provided in the health care reform legislation because of provisions in the new pathway that favor brands, Jeff George, the head of Sandoz, predicted
U.S. Biosimilars: The "Devil's In The Details," Sandoz Chief Says
Regulatory pathways like 505(b)(2) and BLA, not the new one created through health care legislation, may be best for biosimilars, Sandoz CEO George says.